1-[(2,5-二甲基苯基)磺酰基]哌嗪 | 524711-33-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[(2,5-二甲基苯基)磺酰基]哌嗪
• 英文名称: 1-[(2,5-Dimethylphenyl)sulfonyl]piperazine
• 英文别名: 1-(2,5-dimethylphenyl)sulfonylpiperazine
• CAS: 524711-33-9
• 化学式: C₁₂H₁₈N₂O₂S
• mdl: MFCD03444524
• 分子量: 254.353
• InChiKey: UNCDXZPJNCWORR-UHFFFAOYSA-N

物化性质

• 沸点：
  412.1±55.0 °C(Predicted)
• 密度：
  1.192±0.06 g/cm3(Predicted)
• 溶解度：
  >38.2 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 chromeno[4,3-c]pyrazol-4(2H)-one 、 1-[(2,5-二甲基苯基)磺酰基]哌嗪 以 乙醇 为溶剂， 以58%的产率得到2-((4-((2,5-dimethylphenyl)sulfonyl)piperazin-1-yl)methyl)chromeno[4,3-c]pyrazol-4(2H)-one
  参考文献：
  名称：

  Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα

  摘要：

  PI3K signal pathway plays a vital role in cellular functions and becomes an attractive approach for cancer therapy. Herein, a new series of novel chromeno[4,3-c]pyrazol-4(2H)-one derivatives bearing sulfonylpiperazine based on the PI3K inhibitors and our previous research. They were screened for their PI3K inhibitory activities and anticancer effects in vitro. Biological studies indicated that compound 7m revealed the remarkable antiproliferative activity (IC50 ranging from 0.03 to 0.09 mu M) against four cancer cell lines (A549, Huh7, HL60 and HCT-116). Besides, compound 7m displayed a certain selective for PI3K alpha (IC50 = 0.009 mu M) over PI3K beta, gamma and delta, and meanwhile, it can remarkable decreased the expression level of p-Akt (Ser473) and p-S6K. In addition, compound 7m could not only induce HCT-116 cell arrest at G1 phase in a dose-dependent manner, but also induce cell apoptosis via upregulation of Bax and cleaved-caspase 3/9, and downregulation of Bcl-2. Besides, compound 7m can remarkably inhibit the growth of tumor in vivo. The above results suggested that compound 7m could be considered as a promising PI3K alpha inhibitor. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111630
• 作为产物：
  描述：

  哌嗪 、 2,5-二甲基苯磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-[(2,5-二甲基苯基)磺酰基]哌嗪
  参考文献：
  名称：

  Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα

  摘要：

  PI3K signal pathway plays a vital role in cellular functions and becomes an attractive approach for cancer therapy. Herein, a new series of novel chromeno[4,3-c]pyrazol-4(2H)-one derivatives bearing sulfonylpiperazine based on the PI3K inhibitors and our previous research. They were screened for their PI3K inhibitory activities and anticancer effects in vitro. Biological studies indicated that compound 7m revealed the remarkable antiproliferative activity (IC50 ranging from 0.03 to 0.09 mu M) against four cancer cell lines (A549, Huh7, HL60 and HCT-116). Besides, compound 7m displayed a certain selective for PI3K alpha (IC50 = 0.009 mu M) over PI3K beta, gamma and delta, and meanwhile, it can remarkable decreased the expression level of p-Akt (Ser473) and p-S6K. In addition, compound 7m could not only induce HCT-116 cell arrest at G1 phase in a dose-dependent manner, but also induce cell apoptosis via upregulation of Bax and cleaved-caspase 3/9, and downregulation of Bcl-2. Besides, compound 7m can remarkably inhibit the growth of tumor in vivo. The above results suggested that compound 7m could be considered as a promising PI3K alpha inhibitor. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111630

文献信息

• Novel Derivatives
  申请人：Heer Jag Paul

  公开号：US20100016330A1

  公开（公告）日：2010-01-21

  The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca v 2.2 calcium channels is beneficial.

  本发明涉及新颖的哌嗪衍生物；其制备方法；含有这些衍生物的药物组合物；以及利用这些衍生物在治疗中治疗阻断Ca v 2.2钙通道有益的疾病。
• 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES
  申请人：Beswick Paul John

  公开号：US20120302746A1

  公开（公告）日：2012-11-29

  The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca v 2.2 calcium channels is beneficial.

  本发明涉及新型哌嗪衍生物；其制备方法；含有这些衍生物的药物组合物；以及利用这些衍生物在治疗阻断Cav2.2钙通道对疾病有益的疗法中的用途。
• US8093249B2
  申请人：——

  公开号：US8093249B2

  公开（公告）日：2012-01-10
• US8288388B2
  申请人：——

  公开号：US8288388B2

  公开（公告）日：2012-10-16
• US8536183B2
  申请人：——

  公开号：US8536183B2

  公开（公告）日：2013-09-17